296 related articles for article (PubMed ID: 14679003)
1. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
3. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
[TBL] [Abstract][Full Text] [Related]
4. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
5. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
[TBL] [Abstract][Full Text] [Related]
6. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
[TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome.
Grinshtein N; Ventresca M; Margl R; Bernard D; Yang TC; Millar JB; Hummel J; Beermann F; Wan Y; Bramson JL
Cancer Gene Ther; 2009 Apr; 16(4):338-50. PubMed ID: 18989352
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide induces differentiation of Th17 cells in cancer patients.
Viaud S; Flament C; Zoubir M; Pautier P; LeCesne A; Ribrag V; Soria JC; Marty V; Vielh P; Robert C; Chaput N; Zitvogel L
Cancer Res; 2011 Feb; 71(3):661-5. PubMed ID: 21148486
[TBL] [Abstract][Full Text] [Related]
13. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication.
Denies S; Cicchelero L; Van Audenhove I; Sanders NN
J Control Release; 2014 Aug; 187():175-82. PubMed ID: 24887014
[TBL] [Abstract][Full Text] [Related]
14. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
15. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
16. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
17. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
18. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice.
Mitrus I; Delić K; Wróbel N; Missol-Kolka E; Szala S
Acta Biochim Pol; 2006; 53(2):357-60. PubMed ID: 16733559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
